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Abstract 
Background: Identification of plasmodial antigens targeted by protective immune mechanisms is important for 
malaria vaccine development. Among functional assays, the neutrophil antibody‑dependent respiratory burst (ADRB) 
induced by opsonized Plasmodium falciparum merozoites has been correlated with acquired immunity to clinical 
malaria in endemic areas, but the target merozoite antigens are unknown. Here, the contribution of antibodies to the 
conserved C‑terminal domain of the P. falciparum merozoite surface protein‑1 (PfMSP1p19) in mediating ADRB was 
investigated in sera from individuals living in two Senegalese villages with differing malaria endemicity.
Methods: Anti‑PfMSP1p19 antibody levels in sera from 233 villagers were investigated and the involvement of anti‑
PfMSP1p19 antibodies in ADRB was explored in a subset of samples using (1) isogenic P. falciparum parasite clones 
expressing P. falciparum or Plasmodium chabaudi MSP1p19; (2) PfMSP1p19‑coated plaque ADRB; and, (3) ADRB trig‑
gering using sera depleted from PfMSP1p19 antibodies by absorption onto the baculovirus recombinant antigen.
Results: ADRB activity correlated with anti‑PfMSP1p19 IgG levels (P < 10−3). A substantial contribution of PfMSP1p19 
antibody responses to ADRB was confirmed (P < 10−4) in an age‑adjusted linear regression model. PfMSP1p19 
antibodies accounted for 33.1 % (range 7–54 %) and 33.2 % (range 0–70 %) of ADRB activity evaluated using isogenic 
merozoites (P < 10−3) and depleted sera (P = 0.0017), respectively. Coating of PfMSP1p19 on plates induced strong 
ADRB in anti‑PfMSP1p19‑positive sera.
Conclusion: These data show that naturally acquired P. falciparum MSP1p19 antibodies are potent inducers of neu‑
trophil ADRB and support the development of PfMSP1p19‑based malaria vaccine using ADRB assay as a functional 
surrogate for protection.
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Background
Plasmodium spp. parasites responsible for malaria 
remain a major global health burden and efforts are being 
intensified to develop effective vaccines and new therapy. 
Plasmodium falciparum, which causes about 600,000 
deaths each year [1], is becoming multi-drug resistant [2, 
3], exacerbating the need for an effective malaria vaccine. 
Merozoite surface proteins (MSPs) are attractive candi-
date antigens for vaccine development and several cur-
rent vaccine candidates are recombinant MSP analogues 
[4, 5]. MSPs are expressed by mature intrahepatic forms 
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and as such, are possible targets of cellular effectors. 
MSPs displayed onto the surface of invasive merozoites 
are directly accessible to host immune effectors in the 
blood, such as antibodies, complement, neutrophils, or 
monocytes [6]. Antibodies against various recombinant 
MSPs have been associated with protection against clini-
cal episodes of P. falciparum malaria in endemic settings 
[7–9]. The exact function of such antibodies is still poorly 
understood. Merozoite-specific neutralizing antibodies 
preventing invasion of red blood cells in human sera were 
evidenced using invasion assays or growth inhibition 
assays (GIA), but no clear correlation with protection 
against malaria morbidity has been documented [9, 10].
There is an increasing body of evidence to associ-
ate protection with presence of cytophilic antibod-
ies [11–13]. Antibody-dependent cellular inhibition 
(ADCI), whereby monocytes activated by antibody-
coated merozoites inhibit development of intracellular 
erythocytic stages has been associated with protection 
in humans [14]. Salmon et  al. [15] and Kumaratilake 
et al. [16] showed that merozoite-specific antibodies can 
induce respiratory bursts from neutrophils (ADRB). The 
mechanism(s) by which antibody triggered ADRB was 
then investigated in more detail using recombinant anti-
bodies by Pleass et al., who demonstrated the implication 
of cytophilic antibodies in ADRB [17, 18]. The respira-
tory burst activity of human polymorphonuclear neutro-
phils (PMN) triggered by P. falciparum merozoites and 
immune IgG from individuals living in endemic areas 
has been previously characterized and quantified [19]. 
Importantly, the antibody-dependent respiratory burst 
(ADRB) activity significantly correlated with acquired 
clinical protection, suggesting that the release of extracel-
lular oxygen radicals by activated PMNs may represent a 
key effector mechanism of naturally acquired immunity 
to malaria [19].
The identification of the merozoite surface antigens 
reacting with opsonizing antibodies and with antibodies 
triggering neutrophil activation is of obvious interest for 
vaccine development as recently investigated in a Plas-
modium yoelii malaria mouse model [20].
Here, the role of human antibodies recognizing the 
C-terminal domain of MSP1, PfMSP1p19, in mediating 
neutrophil ADRB was investigated. Firstly, the correla-
tion between presence of antibodies to the baculovirus-
expressed PfMSP1p19 and ADRB-inducing capacity in 
the sera from people living in endemic areas was ana-
lysed. Secondly, the functional contribution of PfM-
SP1p19-specific antibodies to ADRB was investigated 
using P. falciparum D10 wild type or transgenic D10 mer-
ozoites, expressing the Plasmodium chabaudi MSP1p19 
orthologue [21]. A direct role for PfMSP1p19-specific 
antibodies in ADRB was further assessed using sera 
depleted from specific antibodies by affinity chromatog-
raphy and solid phase ADRB using PfMSP1p19-coated 
plates [20, 22]. Results show that PfMSP1p19-specific 
antibodies account for a good proportion of ADRB activ-
ity, providing further support for the development of 
malaria vaccines including the PfMSP1p19 antigen.
Methods
Study sites, subjects and ethics statement
This study is part of a longitudinal study conducted in 
Dielmo and Ndiop, two Senegalese villages with peren-
nial and seasonal transmission, respectively. The sites, 
population endemicity and the longitudinal surveys car-
ried out have been described previously [23, 24]. In July 
2002, 119 Dielmo and 114 Ndiop villagers were enrolled 
in a longitudinal and cross-sectional study. At the time of 
recruitment, no villagers were symptomatic for malaria. 
The mean age of the Ndiop and Dielmo cohorts was 
25.3  years (range 3.4–80.5) and 21.8  years (range 3.9-
76.9), respectively; the distribution in the different age 
groups is shown in Table 1. Blood samples were collected 
by venous puncture, and sera were stored at −20 °C.
The project protocol and objectives were carefully 
explained to the assembled villagers, and informed con-
sent, annually renewed, was obtained individually from 
all subjects either by signature or by thumbprint on a 
voluntary consent form written in both French and in 
the local language (Wolof and Serere) [24]. This study 
was examined and approved by the Senegalese National 
Health Research Ethics Committee.
Urban samples were from hospitalized adults with 
confirmed severe malaria, living in the unstable hypo-
endemic urban area of Dakar. They were treated at 
Hôpital Principal, Dakar. Samples were collected day 0 
of hospitalization after their use for routine biological 
investigations. This study was approved by ad hoc Ethics 
Committee and informed consent was obtained from all 
participants.
Antigens and antibodies
The soluble recombinant protein corresponding to PfM-
SP1p19 was produced in the baculovirus/insect cell 
expression system in High Five (Invitrogen) insect cells. 
The construct has a C-terminal hexa-histidine tag that 
replaces the GPI-modification signal sequence of the par-
asite protein. Recombinant PfMSP1p19 was purified by 
metallo-affinity chromatography, as described previously 
[25].
A hyper-immune serum pool (HIS) from 30 immune, 
primarily adult residents of Dielmo (mean age 36 years, 
range 9–73  years), and non-immune serum pool (NIS) 
obtained commercially (Calbiotech, France), were the 
positive and negative controls, respectively.
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ELISA analysis
The ELISA protocol used to measure PfMSP1p19 anti-
bodies at a 1:200 serum dilution was essentially as 
described [9, 26, 27], using baculovirus PfMSP1p19 
coated on Immulon-4 plates (Dynatech) at 0.5 µg mL−1. 
For inter-assay comparisons, results were expressed as 
OD-ratios corresponding to OD-sample/OD-naïve. Posi-
tive responders (PR) were individuals with an OD-ratio 
over 2, corresponding to the mean OD of naïve con-
trols + 2SD. High responders (HR) were individuals with 
an OD-ratio >7, i.e. the threshold level previously shown 
to be significantly associated with anti-parasite activity in 
re-infection study in Ndiop [26].
To monitor specific antibody depletions quantitatively, 
samples were analysed at 1:200, 1:400 and 1:800 dilu-
tions, and an arbitrary titre was extrapolated using a 
four-parameter logistic fit from a standardized positive 
control regression curve on each plate, determined using 
the HIS pool and serial twofold dilutions starting at 1:200 
[28, 29].
Serum depletion
Sera from high responder individuals to PfMSP1p19 
were selected for the depletion studies. Each serum 
(100 µL) was diluted 1:3 in PBS and incubated with 50 µg 
of recombinant hexa-histidine tagged PfMSP1p19 pro-
tein for 30 min at RT to allow antigen–antibody binding. 
Packed TALON Metal Affinity Resin (Ozyme) pre-equil-
ibrated with PBS (200 µL), was added and incubated with 
gentle mixing for 3 h at room temperature (RT), to allow 
antigen–antibody complex binding via the C-terminal 
hexa-histidine tag. Depleted sera were recovered in the 
supernatant after centrifugation without further dilution, 
so that initial and depleted sera were directly comparable. 
Effective depletion was checked by ELISA.
Parasite culture and merozoite preparation
Plasmodium falciparum parasites (PAM, an FCR3-like 
background) and P. falciparum D10 (D10-PfM3′) or trans-
genic D10 merozoites, in which PfMSP1p19 is replaced by 
the non-cross reactive Plasmodium chabaudi orthologue, 
PcMSP1p19 (also called PcMEGF) [21, 30] were main-
tained in continuous culture on O+ erythrocytes in RPMI 
supplemented with 0.5 % Albumax and 1 μg mL−1 gen-
tamycin, in candle jars [31]. Merozoites were collected as 
described previously [19] from cultures with greater than 
5 % parasitaemia after centrifugation 5 min at 400×g, to 
remove red blood cells (RBCs), followed by a second cen-
trifugation of the supernatant for 20 min at 1500×g.
PMN preparation
PMNs were prepared as described previously [19]. 
Briefly, blood samples from six to seven healthy donors 
were collected into EDTA-K3 tubes, layered onto Ficoll-
Histopaque (density 1.077, Sigma) and centrifuged at RT 
for 30 min at 400×g. PMNs were harvested at the Ficoll-
RBC interface and residual RBCs were lysed by incuba-
tion in 8.32 g L−1 NH4Cl, 0.8 g L−1 sodium bicarbonate, 
and 0.043  g  L−1 EDTA for 8  min at 4  °C. PMNs were 
washed twice with Hank’s balanced salt solution (HBSS), 
enumerated using Trypan blue, and resuspended in PBS 
at 1–5 × 107 cells mL−1.
Chemiluminescence monitoring and determination 
of standardized ADRB index
Chemiluminescence was measured as described previ-
ously [19] using opaque 96-well plates (Berthold), and 
a MicroLumat Plus 96 luminometer (Berthold). Briefly, 
merozoite pellets (40 µL) were incubated with 10 µL of 
test or control sera for at least 30 min at 37 °C. PMN (100 
µL at 1–5 × 107 cells mL−1) and isoluminol (100 µL of 
Table 1 Antibody responses against MSP1p19 in Dielmo and Ndiop villagers tested for ADRB
a Mean [range] antibody levels to PfMSP1p19 expressed in OD-ratio
b Percent of responders (OD-ratio > 2) and of High responders (OD-ratio > 7)
c Mean level and range [min–max] of ADRB measured in villagers’ sera
Age groups (years) N Mean age (years) Anti-PfMSP1p19 levelsa % Positive respondersb % High respondersb ADRBc
DIELMO
 0–6 19 4.6 3.6 [1–9.1] 68 16 154 [46–354]
 7–14 31 10.9 3.5 [1–15] 48 13 231 [40–958]
 ≥15 69 37.4 9.2 [1–16.9] 87 62 380 [106–575]
 All 119 25.3 6.8 [1–16.9] 74 42 305 [40–958]
NDIOP
 0–14 49 8.8 6.4 [1–18.4] 80 37 162 [51–545]
 15–29 33 20.5 9.2 [1–19.7] 88 55 307 [113–1721]
 ≥30 32 43.9 11.9 [1–19.9] 94 69 370 [56–1147]
 All 114 21.8 8.8 [1–19.9] 86 51 262 [51–1721]
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1:100 dilution in PBS of 4 mg mL−1 stock in DMSO) were 
loaded rapidly using an Eppendorf multipipette 4780. To 
facilitate rapid handling, only 40–50 wells per plate were 
used using the HIS as systematic internal control in the 
first and last wells. Plate reading started immediately, and 
continued for 1 h.
Data are presented as standardized activity index of 
merozoite ADRB calculated as
 where rlu maximum HIS is an average of the first and 
last wells on the plate. Only experiments in which the 
rlu maximum HIS was ≥100 (≥6 ×  background), were 
included in the analyses. An additional internal control 
with the same positive serum was included in each run.
Chemiluminescence assay using antigen coated on plates
Baculovirus PfMSP1p19 was coated on white Nunc 
opaque Maxisorp plates (Dynatech) at 1  µg/mL over-
night at 4  °C. Plates were then washed three times with 
PBS-Tween-0.05 % and blocked for 1 h with PBS-BSA2 % 
before a second wash. Native (undecomplemented) sera 
diluted 1:5 in PBS were then added and incubated for 
1 h at 37 °C. PMN and isoluminol were then added as for 
classical ADRB (see above) [19, 22], before reading in the 
MicroLumat Plus 96 luminometer (Berthold).
Statistical analysis of ADRB assay data
ELISA and/or ADRB data were analysed for statistical sig-
nificance using the Wilcoxon signed rank test and the Spear-
man rank correlation test for non-normally distributed data, 
and P values  <0.05 were considered significant. Multiple 
regression analysis including age of individuals, Ab response 
to PfMSP1p19 and ADRB was done using R software.
Results
Prevalence and levels of PfMSP1p19-binding IgG and their 
relationship with antibody-dependent respiratory burst 
activity in individual sera
The prevalence and levels of IgG specific for PfMSP1p19 
were first determined in a set of 233 endemic sera, 
including 119 from Dielmo (holo-endemic) and 114 from 
Ndiop (meso-endemic). Antibody responses expressed 
as ELISA OD ratios are summarized in Table  1. Preva-
lence of IgG to PfMSP1p19 was high, with 74 and 86 % 
of responders in the Dielmo and Ndiop cohorts, respec-
tively. Both seropositivity and IgG levels to PfMSP1p19 
were higher in Dielmo than Ndiop (P  =  0.023 and 
P = 0.009 by Fisher’s exact test and Mann Withney rank 
sum test, respectively).
ADRB and antibodies to PfMSP1p19 correlated 
with age. A quite significant correlation between the 
ADRB index = (rlu maximum sample/rlu maximum HIS)
× 1000
magnitude of ADRB index and IgG responses to PfM-
SP1p19 was found (Rho  =  0.71 and 0.68, P  <  10−3 for 
Dielmo and Ndiop, respectively). Stratification of anti-
body responses to PfMSP1p19 of individuals (Fig.  1) 
into non-responders (NR), positive responders (PR, 
individuals with OD-ratio >2) and high responders (HR; 
individuals with OD-ratio >7) outlined a significant asso-
ciation of ADRB with increasing response to PfMSP1p19 
(P  <  10−3). The significant contribution of PfMSP1p19 
antibody responses to ADRB was confirmed highly sig-
nificant P  <  10−4 in an age-adjusted linear regression 
model.
Naturally acquired antibodies binding to PfMSP1p19 are 
major inducers of ADRB activity
To demonstrate a role for PfMSP1p19-specific IgG in the 
ADRB, assays were carried out using either P. falciparum 
D10 (D10-PfM3′) or transgenic D10 PcMEGF merozo-
ites, in which PfMSP1p19 has been replaced by the non-
cross reactive P. chabaudi homologue, PcMSP1p19 [30], 
such that differences in observed chemiluminescence 
signals can be attributed to antibodies specific for PfM-
SP1p19 [21]. As shown in Fig.  2, comparative ADRBs 
were performed using 21 individual sera with high anti-
PfMSP1p19 ELISA OD-ratios. Chemiluminescence 
elicited by the transgenic PcMEGF merozoites was signif-


















Fig. 1 ADRB responses stratified by anti PfMSP1p19 antibody levels 
in the two villages. ADRB measured in 119 and 114 sera from Dielmo 
and Ndiop, respectively are plotted as function of their anti‑PfM‑
SP1p19 antibodies responses stratified into three levels: non‑respond‑
ers (NR), positive responders (PR, OD ratio > 2) and strong responders 
(SR, OD ratio > 7). The SR level was selected according to previous 
study [21] underlining this critical threshold of antibody levels to 
PfMSP1p19 in Ndiop. Boxplot graphs show that the profile of ADRB 
responses strongly and significantly increase (P < 10−3) with increas‑
ing anti‑PfMSP1p19 antibodies content. The median is indicated by 
a line, the 50 % percentiles indicated by the box limits and the upper 
and lower 25 % by whiskers
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sera (P < 10−3), varying from 7 to 54 % inhibition, with 
a mean of 33.1  %. Importantly a similar reduction of 
chemiluminescence was observed using the HIS pool of 
30 immune antisera, none of which was selected for pres-
ence of PfMSP1p19-binding antibodies (and thus unre-
lated to the 21 individually sera analysed above). These 
results indicate that antibodies induced by natural P. fal-
ciparum infection to this single conserved antigen repre-
sent a good proportion of antibodies mediating reactive 
oxygen species (ROS) release by neutrophils.
Impact of PfMSP1p19 antibody depletion on ADRB activity
To explore contribution of PfMSP1p19-specific antibody 
to the ADRB readout, another approach was developed, 
involving depletion of specific antibodies by adsorption 
on the recombinant antigen. Efficiency of depletion mon-
itored by ELISA on the antigen showed that the deple-
tion protocol was highly effective. Median titre units 
decreased from 511 to 1 after anti-PfMSP1p19 depletion, 
indicating a depletion efficiency >99 %.
Figure  3 summarizes the effect of anti-PfMSP1p19 
antibody depletion on ADRB activity. A paired com-
parison of ADRB indexes before and after depletion of 
anti-PfMSP1p19 in 21 individual immune sera showed a 
33.2 % average reduction after depletion (range 0–70 %; 
P  =  0.0017), confirming the results obtained using the 
transgenic D10 PcMEGF merozoites.
Solid-phase ADRB driven by PfMSP1p19 antigen 
and human sera
To further explore the contribution of PfMSP1p19-spe-
cific antibody to ADRB, solid-phase ADRB was carried 
out using plates coated with the recombinant PfMSP1p19 
antigen as sole antigen in the assay. A set of 21 sera from 
Dielmo and Ndiop and four sera from hospitalized urban 
malaria with variable levels of anti-PfMSP1p19 IgG were 
simultaneously tested.
The kinetics of luminescence and ROS production was 
different than from the previously described ADRB assay 
using entire merozoites [19]. The peak of luminescence, 
measured using isoluminol occurred around 30 min, i.e. 
later than the peak occurring within 5 min in the usual 
the standard assay (Additional file 1) [19, 22]. High levels 
of luminescence were observed (around 2–3000 rlu), the 
highest signal being produced by the immune IgG posi-
tive control. Background rlu from the commercial naive 
control pool of sera was around 300 and very low sig-
nals were observed with individual naive European sera 
(rlu < 40).
The individual levels of ADRB measured in the set of 
sera are shown Fig.  4. The solid-phase PfMSP1p19-spe-
cific ADRB index varied depending on the individual. 
Importantly, there was a positive and significant rela-
tionship between IgG to PfMSP1p19 and solid-phase 
ADRB measures, with a correlation coefficient rho = 0.64 
(P < 10−3).
Discussion
It has been previously demonstrated that PMN from 
healthy donors produce a respiratory burst in response to 
merozoites and IgG1 and/or IgG3 antibodies in sera from 
individuals living in malaria-endemic areas [19]. It was 
further shown that the merozoite-triggered ADRB activ-



























Fig. 2 Naturally‑acquired anti‑PfMSP1p19 antibodies are major inducers of ADRB activity against P. falciparum merozoites. a ADRB chemilumines‑
cence readout for 21 sera with high anti‑PfMSP1p19 OD‑ratios tested using either P. falciparum D10 merozoites (D10‑PfM3′, black bars) or transgenic 
D10 merozoites in which the P. falciparum MSP1p19 gene was replaced by its P. chabaudi orthologue (D10‑PcMEGF, black bars). D10‑PfM3′ and 
D10‑PcMEGF merozoites were tested in the same plate, with the same polymorphonuclear cells batch. b Boxplot graph showing the significant 
(P < 10−3) overall distribution of ADRB generated using sera and D10‑PfM3′ or D10‑PcMEGF transgenic merozoites. The median is indicated by a 
line, the 50 % percentiles indicated by the box limits and the upper and lower 25 % by whiskers
Page 6 of 9Joos et al. Malar J  (2015) 14:409 
with naturally acquired clinical protection from malaria. 
The work presented here identifies PfMSP1p19 as a tar-
get of antibodies mediating ADRB activity in sera from 
humans immunized by repeated exposure to P. falcipa-
rum infection. IgG responses to the recombinant PfM-
SP1p19 were highly correlated with ADRB activity in the 
two settings analysed. Importantly, depletion of sera from 
antibodies specific for PfMSP1p19 or use of merozoites 
expressing the non-cross-reactive rodent orthologue, 
PcMSP1p19 caused a significant reduction in the capac-
ity of hyper-immune and high responder sera to medi-
ate ADRB activity. Finally, ADRB could be triggered by 
incubating immune sera with recombinant PfMSP1p19 
as sole target antigen.
The clinical implications of this work are two-fold. First, 
the results presented here strongly implicate human IgG 
antibodies’ ability to react with the native PfMSP1p19 
antigen displayed onto the merozoite surface as media-
tors of ADRB activity. Importantly, this target antigen 
exhibits limited antigenic diversity, an essential feature of 
vaccine candidates aiming to provide durable protection 
against polymorphic field parasite populations. Numer-
ous sero-epidemiology studies have documented a high 
seroprevalence of antibodies to PfSMP1p19 [8, 9, 27, 32, 
33]. The data observed here with two Senegalese cohorts 
living in different endemic conditions and moreover 
gathering different ethnic groups [34] are thus likely to be 
relevant for multiple endemic settings. Natural antibod-
ies to PfMSP1p19 accounted for approximately 30  % of 
the ADRB activity of immune human sera in this work. 
Interestingly, O’Donnell et  al. [30] using immune sera 
from Papua New Guinea and the same isogenic para-
site strains showed that antibodies to PfMSP1p19 were 
responsible for about 25  % of the erythrocyte invasion 
inhibitory response of the human sera in vitro [30]. Thus 
these two assays provide a similar evaluation of the con-
tribution of the anti-PfMSP1p19 specificity within the 
pool of antibodies reacting with merozoites. This indi-
cates that indeed antibodies to PfMSP1p19 are a major 
component of the naturally-acquired, infection-elicited 
anti-merozoite response. A recent study conducted in the 
P. yoelii mouse model showed that vaccination with the 
AdHu5-PyMSP142 construct did not induce anti-PyM-































Fig. 3 Effect of anti‑PfMSP1p19 depletion on ADRB activity against P. falciparum merozoites. A set of 21 sera were depleted from anti‑PfMSP1p19 
antibodies using metal affinity immuno‑adsorbent. a The ADRB level of each serum pair (undepleted and depleted, black and light bars, respec‑
tively) was plotted in increasing order of ADRB level of undepleted sera. b Boxplot graph showing the significant (P < 10−3) overall drop of ADRB 
from initial vs depleted sera. All sera selected had initial high levels of anti‑PfMSP1p19 antibodies. The median is indicated by a line, the 50 % 























Ndiop (mesoendemic) Dielmo (holoendemic) Urban
Fig. 4 ADRB activity of a set of 24 sera in the solid-phase assay using 
PfMSP1p19‑coated plates. Histograms of ADRB activity measured 
using PfMSP1p19‑coated in 9, 11 and 4 sera from Ndiop (light grey), 
Dielmo (medium grey) and urban malaria (dark grey), respectively, 
plotted in increasing order of ADRB units, respectively. The sera were 
chosen irrespective of their level of antibodies to PfMSP1p19 antigen
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antibodies contributing to ADRB were however observed 
in naïve as well as vaccinated mice after a primary infec-
tion, suggesting that infection elicits such antibodies [20].
Second, the data show that the baculovirus recombi-
nant PfMSP1p19 recapitulates here the functional trig-
gering activity of the merozoite-displayed native antigen. 
This is important information for vaccine development. 
Plasmodium MSP1p19 is composed of two intimately 
associated EGF domains, including 10–12 cysteines and 
five to six disulfide bonds, constituting an overall con-
formation not easily reproduced in lower order expres-
sion systems [35, 36], and human antibody recognition 
of PfMSP1p19 is totally conformation dependent [25, 
37]. Moreover, evidence from the literature points to 
the potential importance of proper MSP1p19 conforma-
tion in evaluating the effectiveness of specific antibody 
responses. Anti-baculovirus PfMSP1p19 IgG levels in 
endemic sera from Dielmo and Ndiop were previously 
shown to correlate with both erythrocyte invasion inhi-
bition by P. falciparum merozoites in  vitro, and clinical 
protection from P. falciparum malaria in an age-adjusted 
multivariate analysis [9] (confirmed in two subsequent 
studies, R. Perraut and ML Varela, unpublished data). 
These results contrast with those of Roussilhon et  al. 
[13] using sera from the same Senegalese sites, indicat-
ing no correlation of clinical protection with antibodies 
to a recombinant PfMSP1-19 construct corresponding to 
a single EGF domain with unlikely resemblance to native 
PfMSP1p19 [35, 36]. Similarly Dodoo et  al. [32] found 
that IgG1 specific for baculovirus PfMSP1p19 was corre-
lated with protection from clinical malaria in Ghanaian 
children, whereas a previous study in the same location 
using Escherichia coli GST-PfMSP1p19 fusion antigens 
showed no such association [38].
In the work reported here, focus was on IgG. However, 
ADRB was measured with immune sera, which might 
also contain specific IgA. The contribution of IgA to the 
observed responses remains to be investigated, as IgA 
has been shown to induce respiratory bursts to merozo-
ites and MSP1-19 via FcαR (CD89), which is constitu-
tively expressed by neutrophils [18].
The association of antibodies to PfMSP1p19 with pro-
tection is incompletely captured using parameters such 
as antibody levels [7, 9, 13, 26, 27, 32, 38, 39] or GIA [8, 
9]. The association with ADRB, itself associated with pro-
tection against clinical malaria, may somehow combine 
previous observations: high levels of anti-PfMSP1p19 
antibodies that recognize the merozoite surface-displayed 
antigen may altogether inhibit invasion, efficiently trigger 
ADRB and possibly ADCI. These functional read-outs are 
not mutually exclusive, reflecting an association of anti-
bodies with the native antigen on the merozoite surface. 
ADRB is rapid and as such stands out as a convenient 
assay for monitoring the anti-merozoite activity in human 
sera, and an interesting in vitro surrogate of clinical pro-
tection relevant for MSP-based vaccine candidates.
Here, three experimental approaches were used to 
study the contribution of specific antibodies to ADRB. 
Use of isogenic merozoites was appropriate for MSP1p19, 
because its function is apparently based entirely on its 2 
EGF-domain structure, and can be brought about by an 
orthologous domain with differing antigenicity. This fea-
ture is unusual and may not apply to other antigens of 
interest [21]. Moreover, isogenic lines pairs expressing 
or not a specific antigen, are still rare. The data shown 
here validate the depletion approach and the solid-phase 
ADRB approach for the evaluation of other MSP vaccine 
candidates using the ADRB assay. The depletion proto-
col depended on using hexa-histidine-tagged antigens, 
which allowed the formation of antigen–antibody com-
plexes in solution and subsequent removal by binding to 
the metallo-affinity resin, which was critical for efficient 
depletion. This methodology should be readily adapt-
able to antigens carrying other specific tags and presents 
the advantage of not requiring preparation of specific 
immuno-affinity chromatography reagents. The antigen-
coated ADRB proved a convenient test for functional 
screening of polyclonal sera for single antigen specificity 
such as for PfMSP1p19. However, the stimulation is rather 
qualitative, with a positive but not very strong correlation 
(65  %) with level of antibodies measured by ELISA. The 
solid phase ADRB, where PMN activation is detected by 
the use of isoluminol, i.e., monitoring predominantly 
extracellular ROS, differs from the rapid peak response 
(within 5 min) in standard ADRB using merozoites [19]. 
Kapeslki et  al. reported that the peak of luminescence 
occurred later (20  min) when non-decomplemented 
plasma are used [22]. However, such a solid-phase test 
is easier of use than merozoite-based ADRB. Further 
improvement is required for optimization e.g. using IgG 
instead of sera, HBSS medium instead of PBS [40], lumi-
nol instead of isoluminol [22] and should conveniently 
complement the process of development for functional 
analysis targeting merozoite-derived vaccine candidates.
Conclusions
The results presented here show that antibodies to a sin-
gle small conserved antigen, PfMSP1p19, are responsible 
for a good proportion of neutrophil ADRB, an activity 
that has been correlated with protection from clinical P. 
falciparum malaria in endemic areas. They provide fur-
ther support for development of baculovirus recombi-
nant PfMSP1p19 as a vaccine candidate. Importantly, 
the work opens the door to a new approach for the func-
tional analysis of antibodies to other merozoite surface 
antigens, as a complement to the GIA and ADCI assays.
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